Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focusing on neurogenetic medicines, has granted inducement awards to new employee Eric Hall, Ph.D., M.B.A. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option for 36,000 shares, effective July 22, 2024, with a ten-year term and an exercise price of $8.77 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 18,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to Dr. Hall's continued employment with Voyager and the terms of their respective award agreements.
Voyager Therapeutics (Nasdaq: VYGR), un'azienda biotecnologica che si concentra su medicinali neurogenetici, ha concesso premi di indotto al nuovo dipendente Eric Hall, Ph.D., M.B.A. I premi, approvati dal Comitato per la Compensazione secondo la Regola di Vettura Nasdaq 5635(c)(4), comprendono:
1. Un'opzione su azioni non qualificate per 36.000 azioni, efficace dal 22 luglio 2024, con un termine di dieci anni e un prezzo di esercizio di $8.77 per azione. Matura su un periodo di quattro anni: 25% dopo un anno, poi 75% mensilmente per tre anni.
2. Unità di azioni vincolate per 18.000 azioni, efficace dal 1 ottobre 2024, che maturano annualmente in rate uguali per tre anni.
Entrambi i premi sono soggetti alla continua occupazione del Dr. Hall con Voyager e ai termini dei rispettivi accordi di premio.
Voyager Therapeutics (Nasdaq: VYGR), una empresa de biotecnología centrada en medicamentos neurogenéticos, ha otorgado premios de incentivo al nuevo empleado Eric Hall, Ph.D., M.B.A. Los premios, aprobados por el Comité de Compensación bajo la Regla de Cotización Nasdaq 5635(c)(4), incluyen:
1. Una opción de acciones no calificadas para 36,000 acciones, efectiva a partir del 22 de julio de 2024, con un plazo de diez años y un precio de ejercicio de $8.77 por acción. Se adquiere durante cuatro años: 25% después de un año, luego 75% mensualmente durante tres años.
2. Unidades de acciones restringidas para 18,000 acciones, efectivas a partir del 1 de octubre de 2024, que se adquieren anualmente en cuotas iguales durante tres años.
Ambos premios están sujetos a la continuación del empleo del Dr. Hall con Voyager y a los términos de sus respectivos acuerdos de premio.
Voyager Therapeutics (Nasdaq: VYGR), 신경 유전 의학에 주력하는 생명공학 회사가 새로운 직원 Eric Hall, Ph.D., M.B.A.에게 유인 보상을 수여했습니다. 보상은 Nasdaq 상장 규정 5635(c)(4)에 따라 보상위원회에서 승인된 것으로, 다음과 같은 내용이 포함됩니다:
1. 36,000주에 대한 비정규 주식 옵션으로, 2024년 7월 22일에 효력이 발생하며, 10년의 기간과 주당 $8.77의 행사가격을 가집니다. 4년 동안 배분됩니다: 1년 후 25%, 이후 3년 동안 매달 75%.
2. 18,000주에 대한 제한 주식 단위로, 2024년 10월 1일부터 효력이 발생하며, 3년에 걸쳐 매년 동일한 비율로 배분됩니다.
두 가지 보상 모두 드. 홀의 Voyager와의 지속적인 고용 및 해당 보상 계약의 조건에 따라 달라집니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise de biotechnologie axée sur les médicaments neurogénétiques, a accordé des primes d'incitation au nouvel employé Eric Hall, Ph.D., M.B.A. Les primes, approuvées par le Comité de rémunération en vertu de la règle de cotation Nasdaq 5635(c)(4), comprennent :
1. Une option d'achat d'actions non qualifiée pour 36 000 actions, prenant effet le 22 juillet 2024, avec une durée de dix ans et un prix d'exercice de 8,77 $ par action. Elle acquiert des droits sur quatre ans : 25 % après un an, puis 75 % par mois pendant trois ans.
2. Des unités d'actions restreintes pour 18 000 actions, prenant effet le 1er octobre 2024, acquérant des droits annuellement en paiements égaux pendant trois ans.
Les deux primes sont soumises à la poursuite de l'emploi du Dr Hall auprès de Voyager et aux termes de leurs accords de primes respectifs.
Voyager Therapeutics (Nasdaq: VYGR), ein Biotechnologieunternehmen, das sich auf neurogenetische Medikamente konzentriert, hat Anreizvergütungen an den neuen Mitarbeiter Eric Hall, Ph.D., M.B.A. gewährt. Die Vergütungen, die vom Vergütungsausschuss gemäß der Nasdaq-Zulassungsregel 5635(c)(4) genehmigt wurden, umfassen:
1. Eine nicht qualifizierte Aktienoption für 36.000 Aktien, die ab dem 22. Juli 2024 wirksam wird, mit einer Laufzeit von zehn Jahren und einem Ausübungspreis von 8,77 USD pro Aktie. Sie wird über einen Zeitraum von vier Jahren fällig: 25% nach einem Jahr, danach 75% monatlich über drei Jahre.
2. Eingeschränkte Aktieneinheiten für 18.000 Aktien, die ab dem 1. Oktober 2024 wirksam werden und über drei Jahre hinweg jährlich in gleichen Raten fällig werden.
Beide Vergütungen unterliegen der fortgesetzten Anstellung von Dr. Hall bei Voyager und den Bedingungen ihrer jeweiligen Vergütungsvereinbarungen.
- Attraction of new talent with expertise (Ph.D., M.B.A.) to the company
- Alignment of employee interests with company performance through equity-based compensation
- Potential dilution of existing shareholders' equity due to new stock issuance
LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric Hall, Ph.D., M.B.A. that, among other things, provides for the grant to Dr. Hall of a non-qualified stock option and restricted stock units as an inducement material to Dr. Hall’s entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on July 22, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024.
The stock option award to Dr. Hall provides for the purchase of an aggregate of 36,000 shares of Voyager’s common stock, and the restricted stock unit award to Dr. Hall will represent 18,000 shares of Voyager’s common stock. The stock option has a ten-year term and an exercise price of
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
What inducement grants did Voyager Therapeutics (VYGR) announce on July 23, 2024?
What is the exercise price and vesting schedule for the stock option granted by Voyager Therapeutics (VYGR)?
When will the restricted stock units granted by Voyager Therapeutics (VYGR) become effective?
How do the inducement grants align with Nasdaq listing rules for Voyager Therapeutics (VYGR)?
